- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 250 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- July 2024
- 148 Pages
Global
From €2730EUR$2,999USD£2,318GBP
- Report
- June 2023
- 840 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- July 2022
- 600 Pages
Global
From €3004EUR$3,300USD£2,551GBP
- Report
- January 2023
- 132 Pages
Global
From €4050EUR$4,450USD£3,440GBP
- Report
- January 2022
- 90 Pages
Europe
From €4323EUR$4,750USD£3,672GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2731EUR$3,000USD£2,319GBP
Cervarix is a cancer vaccine developed by GlaxoSmithKline (GSK) to protect against two types of Human Papillomavirus (HPV) that cause cervical cancer. It is a recombinant vaccine, meaning it is made from a combination of proteins from the virus. Cervarix is administered as a three-dose series over a six-month period. It is approved for use in females aged 9 to 25 years old.
Cervarix is one of several cancer vaccines available on the market. Other cancer vaccines include Gardasil, which is also used to protect against HPV, and Provenge, which is used to treat prostate cancer.
The Cervarix market is highly competitive, with several major pharmaceutical companies competing for market share. These include GSK, Merck, Pfizer, and Sanofi. Additionally, there are several smaller companies that are developing cancer vaccines, such as Immunovaccine and Oncolytics Biotech. Show Less Read more
